p53-dependent and cell specific epigenetic regulation of the polo-like kinases under oxidative stress

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Ward, Alejandra ^a   Hudson, John W ^a  

^a UNIVERSITY OF WINDSOR   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

POLO LIKE KINASE; POLO LIKE KINASE 4; PROTEIN P53; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER SUSCEPTIBILITY; CELL HYPOXIA; CELL SPECIFICITY; CELL STRAIN; CELL STRAIN HEP3B; CELL STRAIN SAOS 2; CELL STRESS; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; EMBRYO; EMBRYO CELL; EPIGENETICS; FIBROBLAST; GENE EXPRESSION; GENE REPRESSION; GENETIC REGULATION; GENETIC SUSCEPTIBILITY; HEPG2 CELL LINE; HUMAN; HUMAN CELL; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MOUSE; MULTIGENE FAMILY; NONHUMAN; OSTEOSARCOMA CELL; OXIDATIVE STRESS; PLK1 GENE; PLK4 GENE; POLO LIKE KINASE GENE; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROTEIN DEPLETION; PROTEIN FUNCTION; PROTEIN MODIFICATION; SOLID TUMOR; TUMOR MICROENVIRONMENT;

ANIMALS; CELL CYCLE PROTEINS; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEP G2 CELLS; HUMANS; MICE; OXIDATIVE STRESS; PROMOTER REGIONS, GENETIC; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84899562295     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087918     Document Type: Article

References (62)

1. Syed N, Smith P, Sullivan A, Spender LC, Dyer M, et al. (2006) Transcriptional silencing of Polo-like kinase 2 (SNK/PLK2) is a frequent event in B-cell malignancies. Blood 107: 250-256. (Pubitemid 43053549)
2. Ko MA, Rosario CO, Hudson JW, Kulkarni S, Pollett A, et al. (2005) Plk4 haploinsufficiency causes mitotic infidelity and carcinogenesis. Nat Genet 37: 883-888. (Pubitemid 41077116)
3. Knecht R, Elez R, Oechler M, Solbach C, von Ilberg C, et al. (1999) Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck. Cancer Res 59: 2794-2797. (Pubitemid 29283110)
4. Macmillan JC, Hudson JW, Bull S, Dennis JW, Swallow CJ (2001) Comparative expression of the mitotic regulators SAK and PLK in colorectal cancer. Ann Surg Oncol 8: 729-740. (Pubitemid 32952489)
5. Wang R, Song Y, Xu X, Wu Q, Liu C (2013) The expression of Nek7, FoxM1, and Plk1 in gallbladder cancer and their relationships to clinicopathologic features and survival. Clin Transl Oncol 15: 626-632.
6. Takai N, Hamanaka R, Yoshimatsu J, Miyakawa I (2005) Polo-like kinases (Plks) and cancer. Oncogene 24: 287-291. (Pubitemid 40188609)
7. Liu L, Zhang CZ, Cai M, Fu J, Chen GG, et al. (2012) Downregulation of polo-like kinase 4 in hepatocellular carcinoma associates with poor prognosis. PLoS One 7: e41293.
8. Syed N, Coley HM, Sehouli J, Koensgen D, Mustea A, et al. (2011) Polo-like kinase Plk2 is an epigenetic determinant of chemosensitivity and clinical outcomes in ovarian cancer. Cancer Res 71: 3317-3327.
9. Pellegrino R, Calvisi DF, Ladu S, Ehemann V, Staniscia T, et al. (2010) Oncogenic and tumor suppressive roles of polo-like kinases in human hepatocellular carcinoma. Hepatology 51: 857-868.
10. Ward A, Morettin A, Shum D, Hudson JW (2011) Aberrant methylation of Polo-like kinase CpG islands in Plk4 heterozygous mice. BMC Cancer 11: 71.
11. Coley HM, Hatzimichael E, Blagden S, McNeish I, Thompson A, et al. (2012) Polo Like Kinase 2 Tumour Suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in ovarian cancer. Oncotarget 3: 78-83.
12. de Carcer G, Escobar B, Higuero AM, Garcia L, Anson A, et al. (2011) Plk5, a polo box domain-only protein with specific roles in neuron differentiation and glioblastoma suppression. Mol Cell Biol 31: 1225-1239.
13. Xie S, Xie B, Lee MY, Dai W (2005) Regulation of cell cycle checkpoints by polo-like kinases. Oncogene 24: 277-286. (Pubitemid 40188608)
14. Andrysik Z, Bernstein WZ, Deng L, Myer DL, Li YQ, et al. (2010) The novel mouse Polo-like kinase 5 responds to DNA damage and localizes in the nucleolus. Nucleic Acids Res 38: 2931-2943.
15. Hu M, Polyak K (2008) Microenvironmental regulation of cancer development. Curr Opin Genet Dev 18: 27-34. (Pubitemid 351694443)
16. Bapat SA, Jin V, Berry N, Balch C, Sharma N, et al. (2010) Multivalent epigenetic marks confer microenvironment-responsive epigenetic plasticity to ovarian cancer cells. Epigenetics 5: 716-729.
17. Campos AC, Molognoni F, Melo FH, Galdieri LC, Carneiro CR, et al. (2007) Oxidative stress modulates DNA methylation during melanocyte anchorage blockade associated with malignant transformation. Neoplasia 9: 1111-1121. (Pubitemid 350255359)
18. Lim SO, Gu JM, Kim MS, Kim HS, Park YN, et al. (2008) Epigenetic changes induced by reactive oxygen species in hepatocellular carcinoma: methylation of the E-cadherin promoter. Gastroenterology 135: 2128-2140, 2140 e2121-2128.
19. Lu Y, Chu A, Turker MS, Glazer PM (2011) Hypoxia-induced epigenetic regulation and silencing of the BRCA1 promoter. Mol Cell Biol 31: 3339-3350.
20. Zochbauer-Muller S, Fong KM, Virmani AK, Geradts J, Gazdar AF, et al. (2001) Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res 61: 249-255. (Pubitemid 32095725)
21. Rofstad EK, Rasmussen H, Galappathi K, Mathiesen B, Nilsen K, et al. (2002) Hypoxia promotes lymph node metastasis in human melanoma xenografts by up-regulating the urokinase-type plasminogen activator receptor. Cancer Res 62: 1847-1853. (Pubitemid 34408512)
22. Postovit LM, Seftor EA, Seftor RE, Hendrix MJ (2006) Influence of the microenvironment on melanoma cell fate determination and phenotype. Cancer Res 66: 7833-7836. (Pubitemid 44299141)
23. Shemirani B, Crowe DL (2002) Hypoxic induction of HIF-1alpha and VEGF expression in head and neck squamous cell carcinoma lines is mediated by stress activated protein kinases. Oral Oncol 38: 251-257. (Pubitemid 34442546)
24. Keith B, Johnson RS, Simon MC (2011) HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer 12: 9-22.
25. Brigati C, Banelli B, di Vinci A, Casciano I, Allemanni G, et al. (2010) Inflammation, HIF-1, and the epigenetics that follows. Mediators Inflamm 2010: 263914.
26. McKenzie L, King S, Marcar L, Nicol S, Dias SS, et al. (2010) p53-dependent repression of polo-like kinase-1 (PLK1). Cell Cycle 9: 4200-4212.
27. Sosa V, Moline T, Somoza R, Paciucci R, Kondoh H, et al. (2013) Oxidative stress and cancer: an overview. Ageing Res Rev 12: 376-390.
28. Kang KA, Zhang R, Kim GY, Bae SC, Hyun JW (2012) Epigenetic changes induced by oxidative stress in colorectal cancer cells: methylation of tumor suppressor RUNX3. Tumour Biol 33: 403-412.
29. O'Hagan HM, Wang W, Sen S, Destefano Shields C, Lee SS, et al. (2011) Oxidative damage targets complexes containing DNA methyltransferases, SIRT1, and polycomb members to promoter CpG Islands. Cancer Cell 20: 606-619.
30. Grewal P, Viswanathen VA (2012) Liver cancer and alcohol. Clin Liver Dis 16: 839-850.
31. Xie S, Wang Q, Wu H, Cogswell J, Lu L, et al. (2001) Reactive oxygen species-induced phosphorylation of p53 on serine 20 is mediated in part by polo-like kinase-3. J Biol Chem 276: 36194-36199.
32. Morettin A, Ward A, Nantais J, Hudson JW (2009) Gene expression patterns in heterozygous Plk4 murine embryonic fibroblasts. BMC Genomics 10: 319.
33. Ando K, Ozaki T, Yamamoto H, Furuya K, Hosoda M, et al. (2004) Polo-like kinase 1 (Plk1) inhibits p53 function by physical interaction and phosphorylation. J Biol Chem 279: 25549-25561. (Pubitemid 38756815)
34. Martin BT, Strebhardt K (2006) Polo-like kinase 1: target and regulator of transcriptional control. Cell Cycle 5: 2881-2885. (Pubitemid 44953940)
35. Swallow CJ, Ko MA, Siddiqui NU, Hudson JW, Dennis JW (2005) Sak/Plk4 and mitotic fidelity. Oncogene 24: 306-312. (Pubitemid 40188612)
36. Li J, Tan M, Li L, Pamarthy D, Lawrence TS, et al. (2005) SAK, a new polo-like kinase, is transcriptionally repressed by p53 and induces apoptosis upon RNAi silencing. Neoplasia 7: 312-323. (Pubitemid 40664220)
37. Nakamura T, Saito H and Takekawa M (2013) SAPK pathways and p53 cooperatively regulate PLK4 activity and centrosome integrity under stress. Nat Commun 4: 1775.
38. Zhang H, He J, Li J, Tian D, Gu L, et al. (2013) Methylation of RASSF1A gene promoter is regulated by p53 and DAXX. Faseb J 27: 232-242.
39. Le Gac G, Esteve PO, Ferec C, Pradhan S (2006) DNA damage-induced down-regulation of human Cdc25C and Cdc2 is mediated by cooperation between p53 and maintenance DNA (cytosine-5) methyltransferase 1. J Biol Chem 281: 24161-24170. (Pubitemid 44274190)
40. Hervouet E, Vallette FM, Cartron PF (2009) Dnmt3/transcription factor interactions as crucial players in targeted DNA methylation. Epigenetics 4: 487-499.
41. Berglind H, Pawitan Y, Kato S, Ishioka C, Soussi T (2008) Analysis of p53 mutation status in human cancer cell lines: a paradigm for cell line cross-contamination. Cancer Biol Ther 7: 699-708.
42. van Malenstein H, Gevaert O, Libbrecht L, Daemen A, Allemeersch J, et al. (2010) A seven-gene set associated with chronic hypoxia of prognostic importance in hepatocellular carcinoma. Clin Cancer Res 16: 4278-4288.
43. Burns TF, Fei P, Scata KA, Dicker DT, El-Deiry WS (2003) Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (taxol)-exposed cells. Mol Cell Biol 23: 5556-5571. (Pubitemid 36951322)
44. Valenti F, Fausti F, Biagioni F, Shay T, Fontemaggi G, et al. (2011) Mutant p53 oncogenic functions are sustained by Plk2 kinase through an autoregulatory feedback loop. Cell Cycle 10: 4330-4340.
45. Watanabe T, Suzuki T, Natsume M, Nakajima M, Narumi K, et al. (2012) Discrimination of genotoxic and non-genotoxic hepatocarcinogens by statistical analysis based on gene expression profiling in the mouse liver as determined by quantitative real-time PCR. Mutat Res 747: 164-175.
46. Habedanck R, Stierhof YD, Wilkinson CJ, Nigg EA (2005) The Polo kinase Plk4 functions in centriole duplication. Nat Cell Biol 7: 1140-1146.
47. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, et al. (1988) Genetic alterations during colorectal-tumor development. N Engl J Med 319: 525-532.
48. Matthew EM, Hart LS, Astrinidis A, Navaraj A, Dolloff NG, et al. (2009) The p53 target Plk2 interacts with TSC proteins impacting mTOR signaling, tumor growth and chemosensitivity under hypoxic conditions. Cell Cycle 8: 4168-4175.
49. Shahrzad S, Bertrand K, Minhas K, Coomber BL (2007) Induction of DNA hypomethylation by tumor hypoxia. Epigenetics 2: 119-125. (Pubitemid 351682006)
50. Ziech D, Franco R, Pappa A, Panayiotidis MI (2011) Reactive oxygen species (ROS)-induced genetic and epigenetic alterations in human carcinogenesis. Mutat Res 711: 167-173.
51. Turek-Plewa J, Jagodzinski PP (2005) The role of mammalian DNA methyltransferases in the regulation of gene expression. Cell Mol Biol Lett 10: 631-647. (Pubitemid 43161688)
52. Skowronski K, Dubey S, Rodenhiser D, Coomber B (2010) Ischemia dysregulates DNA methyltransferases and p16INK4a methylation in human colorectal cancer cells. Epigenetics 5: 547-556.
53. Park IY, Sohn BH, Choo JH, Joe CO, Seong JK, et al. (2005) Deregulation of DNA methyltransferases and loss of parental methylation at the insulin-like growth factor II (Igf2)/H19 loci in p53 knockout mice prior to tumor development. J Cell Biochem 94: 585-596. (Pubitemid 41420294)
54. Winkles JA, Alberts GF (2005) Differential regulation of polo-like kinase 1, 2, 3, and 4 gene expression in mammalian cells and tissues. Oncogene 24: 260-266. (Pubitemid 40188606)
55. de Carcer G, Manning G, Malumbres M (2011) From Plk1 to Plk5: functional evolution of polo-like kinases. Cell Cycle 10: 2255-2262.
56. Murugan RN, Park JE, Kim EH, Shin SY, Cheong C, et al. (2011) Plk1-targeted small molecule inhibitors: molecular basis for their potency and specificity. Mol Cells 32: 209-220.
57. McInnes C, Wyatt MD (2011) PLK1 as an oncology target: current status and future potential. Drug Discov Today 16: 619-625.
58. Garuti L, Roberti M, Bottegoni G (2012) Polo-like kinases inhibitors. Curr Med Chem 19: 3937-3948.
59. Joeckel TE, Lubbert M (2012) Clinical results with the DNA hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update. Semin Hematol 49: 330-341.
60. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB (1996) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 93: 9821-9826. (Pubitemid 26296693)
61. Li LC, Dahiya R (2002) MethPrimer: designing primers for methylation PCRs. Bioinformatics 18: 1427-1431.
62. Huth A, Vennemann B, Fracasso T, Lutz-Bonengel S, Vennemann M (2013) Apparent versus true gene expression changes of three hypoxia-related genes in autopsy derived tissue and the importance of normalisation. Int J Legal Med 127: 335-344.